Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy
The purpose of this study is to determine if IMC-1121B is safe for patients, and to determine the best dose of IMC-1121B to give to patients.
Advanced Solid Tumors
BIOLOGICAL: IMC-1121B|BIOLOGICAL: 1121B|BIOLOGICAL: 1121B|BIOLOGICAL: 1121B|BIOLOGICAL: 1121B|BIOLOGICAL: 1121B|BIOLOGICAL: 1121B
Number of participants with Adverse Events (AEs), 6 weeks|Maximum Tolerated Dose, 6 weeks
Maximum concentration (Cmax), cohorts 1, 2, 3, 4, 5, 6. and 7, 6 weeks|Minimum concentration (Cmin), cohorts 1, 2, 3, 4, 5, 6. and 7, 6 weeks|Area under concentration (AUC), cohorts 1, 2, 3, 4, 5, 6. and 7, 6 weeks|Half-life (t 1/2), cohorts 1, 2, 3, 4, 5, 6. and 7, 6 weeks|Clearance (Cl) rate drug is completely removed, cohorts 1, 2, 3, 4, 5, 6. and 7, 6 weeks|Volume of distribution (Vss) at steady state, cohorts 1, 2, 3, 4, 5, 6. and 7, 6 weeks|Serum Anti-IMC-1121B Antibody Assessment (immunogenicity), 6 weeks|Change in tumor size from Baseline Measurement, 6 weeks
The purpose of this study is to establish the safety profile and the maximum tolerated dose (MTD) of the anti-VEGFR-2 monoclonal antibody IMC-1121B administered weekly in patients with advanced solid tumors who have not responded to standard therapy or for whom no standard therapy is available.